• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥沙利铂的 Pt(IV)类似物,其电化学还原电位与抗坏血酸还原速率之间的相关性不符合预期。

Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.

机构信息

School of Chemistry, The University of Sydney, NSW 2006, Australia.

出版信息

Chem Commun (Camb). 2012 Jan 21;48(6):847-9. doi: 10.1039/c1cc16647f. Epub 2011 Nov 29.

DOI:10.1039/c1cc16647f
PMID:22124352
Abstract

In contrast to the Pt(IV) derivatives of cisplatin, Pt(IV) derivatives of oxaliplatin do not show the expected correlation between the electrochemical reduction potentials and rates of reduction by ascorbate. This is probably due to the lower ability of the amine and carboxylato ligands to form a bridge with the reducing agents to facilitate electron transfer.

摘要

与顺铂的 Pt(IV)衍生物相反,奥沙利铂的 Pt(IV)衍生物并没有表现出电化学还原电位与抗坏血酸还原速率之间预期的相关性。这可能是由于胺和羧酸盐配体形成桥接与还原剂以促进电子转移的能力较低。

相似文献

1
Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.奥沙利铂的 Pt(IV)类似物,其电化学还原电位与抗坏血酸还原速率之间的相关性不符合预期。
Chem Commun (Camb). 2012 Jan 21;48(6):847-9. doi: 10.1039/c1cc16647f. Epub 2011 Nov 29.
2
A computational mechanistic investigation into the reduction of Pt(iv) prodrugs with two axial chlorides by biological reductants.关于生物还原剂对含两个轴向氯原子的Pt(IV)前药还原作用的计算机理研究。
Chem Commun (Camb). 2017 Jan 24;53(8):1413-1416. doi: 10.1039/c6cc07834f.
3
Antitumor Platinium(IV) Prodrugs: A Systematic Computational Exploration of Their Reduction Mechanism by l-Ascorbic Acid.抗肿瘤铂(IV)前药:l-抗坏血酸还原机制的系统计算研究。
Inorg Chem. 2019 Mar 18;58(6):3851-3860. doi: 10.1021/acs.inorgchem.8b03486. Epub 2019 Mar 7.
4
Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent.铂(IV)前药还原产物对载体配体的结构、体积和还原剂性质的依赖性。
Inorg Chem. 2012 Sep 17;51(18):9694-704. doi: 10.1021/ic300957v. Epub 2012 Aug 24.
5
New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.新型 ctc-[PtCl2(CH3CO2)2(NH3)(Am)] 抗癌前药还原途径。
Chem Commun (Camb). 2010 Mar 21;46(11):1842-4. doi: 10.1039/b925721g. Epub 2010 Feb 12.
6
Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.3,6-二氧杂-1,8-辛二硫醇被铂(IV)抗癌前药和模型配合物氧化:动力学和机理研究。
J Phys Chem B. 2012 Jun 7;116(22):6522-8. doi: 10.1021/jp302600a. Epub 2012 May 22.
7
Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells.赤道和轴向羧基配体对天冬氨酸和半胱氨酸存在下及在 DLD-1 癌细胞内顺铂(IV)配合物动力学惰性的影响。
J Med Chem. 2013 Nov 14;56(21):8757-64. doi: 10.1021/jm401218n. Epub 2013 Oct 31.
8
Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.新型四羧酸根铂(IV)配合物作为卡铂前药。
Dalton Trans. 2012 Dec 21;41(47):14404-14415. doi: 10.1039/c2dt31366a.
9
Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.单核膦配体抗癌 Pt(II) 配合物的氧化:稳定但活性的 Pt(IV) 前药的研究。
Chem Commun (Camb). 2013 May 25;49(42):4806-8. doi: 10.1039/c3cc38416k.
10
Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery.铂(IV)配位聚合物作为细胞内还原响应型主链型接头用于癌症药物递送。
Biomaterials. 2011 Dec;32(34):9136-43. doi: 10.1016/j.biomaterials.2011.08.022. Epub 2011 Sep 1.

引用本文的文献

1
"Non-Classical" Platinum Complexes: A Concise Review.“非经典”铂配合物:简要综述
Int J Mol Sci. 2025 Jun 28;26(13):6270. doi: 10.3390/ijms26136270.
2
Synthesis and anticancer activity of Pt(iv) prodrugs containing 3-bromopyruvic acid as an axial ligand.含3-溴丙酮酸作为轴向配体的铂(IV)前药的合成及抗癌活性
RSC Adv. 2025 Jun 30;15(27):22063-22075. doi: 10.1039/d5ra02064f. eCollection 2025 Jun 23.
3
Multitargeting Pt(IV) Derivatives of Cisplatin or Oxaliplatin Inhibit Tumor Growth in Mice without Inducing Neuropathic Pain.
顺铂或奥沙利铂的多靶点铂(IV)衍生物可抑制小鼠肿瘤生长且不诱发神经性疼痛。
J Med Chem. 2025 Jan 23;68(2):1608-1618. doi: 10.1021/acs.jmedchem.4c02263. Epub 2025 Jan 8.
4
Multiaction Pt(IV) Complexes: Cytotoxicity in Ovarian Cancer Cell Lines and Mechanistic Studies.多作用 Pt(IV) 配合物:在卵巢癌细胞系中的细胞毒性和机制研究。
Inorg Chem. 2024 Aug 12;63(32):14958-14968. doi: 10.1021/acs.inorgchem.4c01586. Epub 2024 Jul 31.
5
Current Status of Novel Multifunctional Targeted Pt(IV) Compounds and Their Reductive Release Properties.新型多功能靶向 Pt(IV) 化合物的现状及其还原释放特性。
Molecules. 2024 Feb 6;29(4):746. doi: 10.3390/molecules29040746.
6
Regulating tumor glycometabolism and the immune microenvironment by inhibiting lactate dehydrogenase with platinum(iv) complexes.通过铂(IV)配合物抑制乳酸脱氢酶来调节肿瘤糖代谢和免疫微环境。
Chem Sci. 2023 Jul 10;14(31):8327-8337. doi: 10.1039/d3sc01874a. eCollection 2023 Aug 9.
7
Platinum(IV)-Gold(I) Agents with Promising Anticancer Activity: Selected Studies in 2D and 3D Triple-Negative Breast Cancer Models.具有显著抗癌活性的铂(IV)-金(I)制剂:二维和三维三阴性乳腺癌模型中的精选研究
Chemistry. 2023 Oct 23;29(59):e202302045. doi: 10.1002/chem.202302045. Epub 2023 Sep 5.
8
Oxali(IV)Fluors: Fluorescence Responsive Oxaliplatin(IV) Complexes Identify a Hypoxia-Dependent Reduction in Cancer Cells.奥沙利铂(IV)氟化物:荧光响应性奥沙利铂(IV)配合物可识别癌细胞中缺氧相关的减少。
J Am Chem Soc. 2023 Jun 21;145(24):12998-13002. doi: 10.1021/jacs.3c03320. Epub 2023 Jun 7.
9
Combination of Drug Delivery Properties of PAMAM Dendrimers and Cytotoxicity of Platinum(IV) Complexes-A More Selective Anticancer Treatment?聚酰胺-胺型树枝状大分子的药物递送特性与铂(IV)配合物的细胞毒性的结合——一种更具选择性的抗癌治疗方法?
Pharmaceutics. 2023 May 17;15(5):1515. doi: 10.3390/pharmaceutics15051515.
10
Synthesis, Characterization and Photoactivation Studies on the Novel Pt(IV)-Based [Pt(OCOCH)(phterpy)] Complex.新型基于 Pt(IV)-[Pt(OCOCH)(phterpy)]配合物的合成、表征及光激活研究。
Int J Mol Sci. 2023 Jan 6;24(2):1106. doi: 10.3390/ijms24021106.